Die Bedeutung von Erythropoietin und seinem Rezeptor für die Prognose humaner Glioblastome

TL;DRAbstract

Introduction: erythropoietin (EPO) is a well-known factor of erythropoiesis and is therefore used to treat anemia in neoplastic disease. In addition, EPO exerts neuroprotective effects via EPO-receptor (EPOR) on neuronal cells. This makes a prophylactic use against neurocognitive impairment caused by radiochemotherapy probable. EPO-/ EPOR signalling, however, has also been recognized in various tumors such as glioblastomas. Several studies during the last years performed in vitro and in vivo reported conflicting results on the effect of EPO on malignant gliomas. We analyzed here the impact of EPO and EPOR expression on the prognosis of human glioblastomas in different treatment groups. Methods: we established retrospectively a bank of human glioblastomas with complete documentation of clinical course and treatment. The expression of EPO (n=64) and EPOR (n=66) was assessed by immunohistochemistry and analyzed with semiquantitative scores. The results were evaluated in univariate and mul

Chat with Paper

AI Agents for this Paper